Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Chiappori

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancerAlberto A Chiappori, Eric Haura, Francisco A Rodriguez, et al.
FEBS Open Bio|July 18, 2019
Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 modelBhaswati Sarcar, Nicholas T Gimbrone, Gabriela Wright, et al.
Cancer Immunology, Immunotherapy : CII|December 29, 2018
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancerAlberto A Chiappori, Charles C Williams, Jhanelle E Gray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumorsAlberto A Chiappori, S Gail Eckhardt, Ronald Bukowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignanciesMayer N Fishman, Christopher R Garrett, George R Simon, et al.
The Oncologist|October 4, 2016
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung CancerAlberto A Chiappori, Gregory A Otterson, Afshin Dowlati, et al.
Sarcoma|February 17, 2016
Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue SarcomaShailaja Raj, Marilyn M Bui, Gregory Springett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignanciesJade Homsi, George R Simon, Chris R Garrett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancerPasi A Jänne, Joachim von Pawel, Roger B Cohen, et al.
Lung Cancer (Amsterdam, Netherlands)|July 27, 2023
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutationsAndreas N Saltos, Ben C Creelan, Tawee Tanvetyanon, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancerAlberto A Chiappori, Eric Haura, Francisco A Rodriguez, et al.
FEBS Open Bio|July 18, 2019
Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 modelBhaswati Sarcar, Nicholas T Gimbrone, Gabriela Wright, et al.
Cancer Immunology, Immunotherapy : CII|December 29, 2018
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancerAlberto A Chiappori, Charles C Williams, Jhanelle E Gray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumorsAlberto A Chiappori, S Gail Eckhardt, Ronald Bukowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignanciesMayer N Fishman, Christopher R Garrett, George R Simon, et al.
The Oncologist|October 4, 2016
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung CancerAlberto A Chiappori, Gregory A Otterson, Afshin Dowlati, et al.
Sarcoma|February 17, 2016
Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue SarcomaShailaja Raj, Marilyn M Bui, Gregory Springett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignanciesJade Homsi, George R Simon, Chris R Garrett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancerPasi A Jänne, Joachim von Pawel, Roger B Cohen, et al.
Lung Cancer (Amsterdam, Netherlands)|July 27, 2023
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutationsAndreas N Saltos, Ben C Creelan, Tawee Tanvetyanon, et al.
Pageof 6